Versor Investments LP Acquires 4,313 Shares of Masimo Co. (NASDAQ:MASI)

During the quarter of the year and as per its recent disclosure to the Securities and Exchange Commission (SEC) Versor Investments LP increased its investment in Masimo Co., a medical equipment provider listed on NASDAQ with symbol MASI by 81%. The institutional investor now holds 9,l591 shares of Masimos stock after acquiring a 4,l3 shares during this period.The total value of Versor Investments LPs stake in Masimo was reported to be $l 279 000 in their recent filing, with the SEC.

Several other investment firms have adjusted their investments in Masimos stock well.NBC Securities Inc. for instance grew its stake in Masimo by 47%.During the quarter NBC Securities Inc.now holds 228 shares of the medical equipment companys stock valued at $30,000 after purchasing an additional 73 shares.GAMMA Investing LLC also raised its stake, in Masimo by 75%during the quarter. HHM Wealth Advisors LLC currently holds 625 shares of the medical equipment providers stock valued at $79k after acquiring a 125 shares in the recent quarter. Moreover I learned that Lazard Asset Management LLC significantly increased its Masimo stake by a 5'730%. As of the tally, in Q1 Lazard Asset Management now possesses 583 shares of the medical equipment providers stock valued at $85k after purchasing an additional 573 shares in the past quarter. It's worth noting that institutional investors and hedge funds collectively own a 85'96 % of the companys stock holdings.

Several recent analyst reports have discussed MASI lately.Raymond James upgraded Masimo from a "market perform" rating to an "rating and established a target price of$170 on November 6th.BTIG Research increased their price target for Masimo from$166 to$170. Provided a "buy" recommendation, on October 14th. On Wednesday the 6th of November year Wells Fargo & Company raised their target price on Masimo from 160 dollars to 171 dollars with an "overweight" rating in a research note. In a research report also dated Wednesday the 6th of November Piper Sandler increased their price estimate for Masimo from 165 dollars to 180 dollars while also giving the company an "rating. On the same day Needham & Company LLC restated a "hold" rating, for Masimos shares. Three stock market analysts have evaluated the companys stock. Two suggest holding onto it while five recommend buying it.Currently rated as a "Moderate Buy " the stock has a target price of $163.

Check out the recent stock analysis, for Masimo in our latest update.

MASI started trading at $161 on Tuesday with its debt to equity ratio standing at 0.5. A quick ratio of 1.15 along with a current ratio of 2.01. Masimo Co.s stock price hit a low of $86.94 and a high of $173.90, over the year. The companys fifty day moving average is around $133.52 while the two hundred day moving average sits at $125.93. With a market capitalization of $8.65 billion and a PE ratio of 111.47 Masimo Co.s beta is reported to be 0.97.

Masimo disclosed its quarterly financial results on Tuesday the 5th of November this year where it revealed earnings per share of $ 98 for the quarter which exceeded the expected consensus of 84 cents by 14 cents bringing a return on equity of almost 15%. The net profit margin stood at 3 and a half percent indicating steady performance in revenue with sales reaching around half a billion dollars vis a vis an estimated consensus just slightly lower, than that figure. In the timeframe last year the company generated earnings of $ ̶6̶3̶ $ ̶6̶3̶ $ .63 per share. Comparatively speaking the companys revenue increased by 5. ̵⁴̵ % In the quarter when contrasted with the period a year ago. Market analysts expect that Masimo Co. Will report an EPS of $ 04, for this fiscal year.

Masimo Corporation creates a range of monitoring technologies and solutions, for connectivity and automation on a global scale. The company provides Masimo Signal Extraction Technology pulse oximetry with motion and low perfusion monitoring to overcome the limitations of traditional pulse oximetry methods. Additionally offered is the Masimo Rainbow SET platform which includes a range of products for monitoring of various blood parameters like carboxyhemoglobin levels and hemoglobin concentration as well as oxygen saturation levels and respiratory rate, among others.

This breaking news update was created using cutting edge narrative science technology and financial information sourced from MarketBeat to deliver precise updates for readers benefit. Prior, to publication MarketBeats editorial team thoroughly reviewed this article. For any inquiries or feedback regarding this article kindly reach out to contact @ marketbeat.com.

Before diving, into Masimos details make sure to listen up.

MarketBeat monitors the rated analysts of Wall Street and their stock recommendations for clients daily identifying the five stocks these analysts are discreetly suggesting to buy before the wider market catches wind of them. Surprisingly Masimo isn't, among them.

Rated analysts suggest that although Masimo is currently rated as a "Moderate Buy " there are five other stocks they consider to be more favorable investment options.